Scott Biller
Director/Board Member chez FOGHORN THERAPEUTICS INC.
Fortune : - $ au 31/03/2024
Profil
Scott Biller is currently an Independent Director at Foghorn Therapeutics, Inc., a Director at Remix Therapeutics, Inc., and a Director at Rome Therapeutics, Inc. Previously, he served as the Chief Scientific Officer at Agios Pharmaceuticals, Inc. from 2010 to 2019.
Prior to that, he was the Vice President & Head-Global Discovery Chemistry at Novartis Institutes for Biomedical Research, Inc. from 2003 to 2010.
He also worked as the VP-Pharmaceutical Candidate Optimization at Bristol-Myers Squibb Pharmaceutical Research Institute from 2001 to 2003.
Dr. Biller obtained his undergraduate degree from Massachusetts Institute of Technology in 1976 and his doctorate degree from California Institute of Technology in 1981.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 29/02/2024 | 0 ( -.--% ) | - $ | 31/03/2024 |
Postes actifs de Scott Biller
| Sociétés | Poste | Début |
|---|---|---|
| FOGHORN THERAPEUTICS INC. | Director/Board Member | 09/01/2020 |
Remix Therapeutics, Inc.
 Remix Therapeutics, Inc. BiotechnologyHealth Technology Remix Therapeutics, Inc. operates as a biotechnology company. It involves in developing small molecule therapies which are designed to reprogram RNA processing to address the underlying drivers of disease. The company was founded by Pete Smith and is headquartered in Cambridge, MA. | Director/Board Member | 01/06/2020 |
Rome Therapeutics, Inc.
 Rome Therapeutics, Inc. BiotechnologyHealth Technology Rome Therapeutics, Inc. develops novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome-vast stretches of uncharted genetic materials. The company was founded by Rosana Kapeller and is headquartered in Cambridge, MA. | Director/Board Member | 01/02/2021 |
Anciens postes connus de Scott Biller
| Sociétés | Poste | Fin |
|---|---|---|
| AGIOS PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 31/12/2019 |
Novartis Institutes for Biomedical Research, Inc.
 Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institutes for Biomedical Research, Inc. conducts biomedical researches. It focuses in the areas of oncology, ophthalmology, diabetes, musculoskeletal disorders, neuroscience, and cardiovascular conditions, other focus areas include discovery chemistry, biologics, pathway biology, and translational medicine. The company was founded on September 10, 2002 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | 01/09/2010 |
| Bristol-Myers Squibb Pharmaceutical Research Institute | Corporate Officer/Principal | 01/07/2003 |
Formation de Scott Biller
| Massachusetts Institute of Technology | Undergraduate Degree |
| California Institute of Technology | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| AGIOS PHARMACEUTICALS, INC. | Health Technology |
| FOGHORN THERAPEUTICS INC. | Health Technology |
| Entreprise privées | 4 |
|---|---|
Novartis Institutes for Biomedical Research, Inc.
Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institutes for Biomedical Research, Inc. conducts biomedical researches. It focuses in the areas of oncology, ophthalmology, diabetes, musculoskeletal disorders, neuroscience, and cardiovascular conditions, other focus areas include discovery chemistry, biologics, pathway biology, and translational medicine. The company was founded on September 10, 2002 and is headquartered in Cambridge, MA. | Commercial Services |
| Bristol-Myers Squibb Pharmaceutical Research Institute | |
Rome Therapeutics, Inc.
Rome Therapeutics, Inc. BiotechnologyHealth Technology Rome Therapeutics, Inc. develops novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome-vast stretches of uncharted genetic materials. The company was founded by Rosana Kapeller and is headquartered in Cambridge, MA. | Health Technology |
Remix Therapeutics, Inc.
Remix Therapeutics, Inc. BiotechnologyHealth Technology Remix Therapeutics, Inc. operates as a biotechnology company. It involves in developing small molecule therapies which are designed to reprogram RNA processing to address the underlying drivers of disease. The company was founded by Pete Smith and is headquartered in Cambridge, MA. | Health Technology |
